NVDA
NVIDIA Corporation
NVDA has the edge over TACT overall, supported by stronger valuation and stronger modeled upside.
TACT
TransAct Technologies Incorporated
TACT trails on the overall score without a compensating advantage in the available component scores.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
TACT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Strong |
TACT's balance sheet is currently strong, and its revenue, profitability and cash flow are stable.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
TACT PE Valuation
TACT has no meaningful PE right now: it lost money over the past year.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
NVDA has the edge over TACT on the outlook, with more favorable earnings expectations.
TACT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect TACT's losses to grow, with revenue growing.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over TACT on earnings quality, reporting a profit while its opponent remains loss making.
TACT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.04 | +$0.82 |
| Q1 2026 | -$0.05 | +$0.83 |
| Q4 2025 | -$0.12 | +$0.86 |
| Q3 2025 | -$0.80 | -$0.60 |
| Q2 2025 | -$0.86 | -$0.81 |
| Q1 2025 | -$0.88 | -1567% |
| Q4 2024 | -$0.98 | -309% |
| Q3 2024 | -$0.20 | -139% |
TACT is still losing money, but far less than before: $0.04 per share over the past year, against $0.98 at its worst in late 2024.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over TACT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over TACT on profitability, with a higher operating margin.
TACT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.9M | +1.1% |
| Q1 2026 | $14.4M | +10% |
| Q4 2025 | $11.5M | +12% |
| Q3 2025 | $13.2M | +21% |
| Q2 2025 | $13.8M | +19% |
| Q1 2025 | $13.1M | +22% |
| Q4 2024 | $10.2M | -23% |
| Q3 2024 | $10.9M | -37% |
TACT's revenue has grown year over year for six quarters in a row: $14M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -0.4% | +1.5 points |
| Q1 2026 | 5.3% | +5.5 points |
| Q4 2025 | -10% | +0.2 points |
| Q3 2025 | 0.1% | +7.8 points |
| Q2 2025 | -1.9% | +1.9 points |
| Q1 2025 | -0.1% | +12 points |
| Q4 2024 | -10% | -6.3 points |
| Q3 2024 | -7.7% | -15 points |
TACT's operating margin was −0.4% last quarter, up 1.5 points from the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over TACT on cash flow, with more consistent year-over-year improvement.
TACT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.1M | -41% |
| Q1 2026 | -$1M | -$855K |
| Q4 2025 | $589K | -75% |
| Q3 2025 | $3.6M | +1278% |
| Q2 2025 | $3.6M | +617% |
| Q1 2025 | -$171K | +$1.4M |
| Q4 2024 | $2.4M | +196% |
| Q3 2024 | $259K | -68% |
TACT generated $5M in free cash flow over the past year, down 13% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over TACT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
TACT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +56K shares |
| 1 year | +2% | +204K shares |
| 3 years | +2.7% | +272K shares |
| 5 years | +15% | +1.3M shares |
| Available history | +33% | +2.5M shares |
TACT has 10M diluted shares, up 2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q3 2019 | — |
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
TACT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -82.4x | Net Cash |
| Q1 2026 | -565.8x | Net Cash |
| Q2 2024 | -26.7x | Net Cash |
| Q1 2024 | -4.0x | Net Cash |
| Q4 2023 | -1.4x | Net Cash |
| Q3 2023 | -1.1x | Net Cash |
| Q2 2023 | -1.2x | Net Cash |
| Q1 2023 | -1.4x | Net Cash |
TACT has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
TACT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.1 | Neutral |
| Stochastic | 47.5 | Neutral |
TACT's weekly RSI is 51 (neutral) and its Stochastic is 48 (neutral).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
TACT PE vs Technology Sector
| Metric | TACT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
TACT has no meaningful PE right now: it lost money over the past year.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
TACT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.88 | 0% above |
| 20 week MA | $5.05 | 3.4% below |
| 50 week MA | $4.35 | 12% above |
| 100 week MA | $4.23 | 15% above |
| 200 week MA | $5.10 | 4.3% below |
TACT has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.
TACT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $7.37 | -31% |
| 2021 | $7.37 | $10.6 | +44% |
| 2022 | $10.6 | $6.18 | -42% |
| 2023 | $6.18 | $6.98 | +13% |
| 2024 | $6.98 | $4.14 | -41% |
| 2025 | $4.14 | $3.92 | -5.3% |
| 2026 YTD | $3.92 | $4.88 | +24% |
TACT has the edge over NVDA on returns for 2026, with the stronger performance.